Every compound below is supplied lyophilised, sealed in a box of 10 vials, verified by HPLC and mass spectrometry to >99% purity, and sourced from Sweden. Prices are per box in USD.
LY3437943, triple GIP/GLP-1/glucagon receptor agonist
A single-molecule triple agonist at the GIP, GLP-1 and glucagon receptors — the most-discussed metabolic research peptide of the current cycle.
LY3298176, dual GIP/GLP-1 receptor agonist
A unimolecular dual agonist of the GIP and GLP-1 receptors, and the compound behind the SURMOUNT and SURPASS trial programmes.
Mod GRF (1-29) + Ipamorelin blend
The classic paired blend: a GHRH analog alongside a selective ghrelin-receptor agonist, studied for complementary action on the GH axis.
TH9507, trans-3-hexenoyl-GHRH(1-44)
A stabilised GHRH(1-44) analog and the only GH-axis compound with regulatory approval specifically for reducing visceral adipose tissue.
A small-molecule NNMT inhibitor studied in adipocyte metabolism and NAD+ salvage research.
Dilute acetic acid, used as a solubilising diluent for peptides with poor neutral-pH solubility.
A prohibitin-targeting peptidomimetic studied for adipose vasculature effects in rodent and primate models.
Bacteriostatic water: sterile water with 0.9% benzyl alcohol, the standard multi-use reconstitution diluent.
A SNAP-25 cleaving neurotoxin used as a research standard in neuromuscular junction studies.
A co-formulated blend of BPC-157 and TB-500 at equal weights.
A co-formulated blend of BPC-157 and TB-500 at equal weights.
A co-formulated blend of BPC-157 and TB-500 at equal weights.
A short peptide bioregulator studied in bronchial epithelium models.
A long-acting amylin analog studied alongside GLP-1 agonism for effects on satiety signalling.
A fixed-ratio co-formulation of cagrilintide and semaglutide, 5mg/5mg presentation.
A porcine-brain-derived peptide preparation studied extensively in neurorestoration literature.
Modified GRF(1-29): a tetrasubstituted GHRH analog without the drug affinity complex.
GHRH(1-29) with a maleimidopropionic acid linker that binds serum albumin, extending half-life to days.
A GLP-1 analog fused to an Fc fragment of human IgG4, giving extended half-life.
The 17-23 fragment of thymosin beta-4, corresponding to the actin-binding motif.
A prohibitin-targeting peptidomimetic studied for adipose vasculature effects.
A four-component blend of BPC-157, TB-500, GHK-Cu and KPV studied in combined repair and dermal research.
The principal endogenous intracellular antioxidant tripeptide (γ-Glu-Cys-Gly).
Native GnRH decapeptide, used as the reference agonist in HPG-axis research.
A hexapeptide GH secretagogue studied for cardiac CD36-mediated effects independent of GH release.
The lipolytic C-terminal fragment of human growth hormone, studied in adipose tissue models.
A selective pentapeptide ghrelin-receptor agonist with minimal effect on cortisol and prolactin.
A KISS1R agonist fragment central to the upstream control of GnRH pulsatility.
A quaternary ammonium compound central to long-chain fatty acid transport into mitochondria.
A lipolytic solution formulation used in aesthetic research contexts.
A once-daily acylated GLP-1 analog and one of the earliest incretin research compounds.
Afamelanotide, a cyclic α-MSH analog studied as a melanocortin-1 receptor agonist.
A non-selective cyclic melanocortin receptor agonist studied across MC1R and MC4R pathways.
A methionine/inositol/choline blend with cyanocobalamin, used in lipotropic research formulations.
The nonapeptide posterior pituitary hormone, studied in social behaviour and smooth muscle research.
A CNTF-derived tetrapeptide studied for neurogenic and BDNF-related effects.
A co-formulated research blend containing retatrutide and tirzepatide.
A GLP-1 receptor agonist with a C18 fatty diacid and Aib substitution giving once-weekly kinetics; the most widely studied incretin analog.
GHRH(1-29), the shortest fully active fragment of growth hormone-releasing hormone.
A dual glucagon/GLP-1 receptor agonist studied in obesity and liver-fat models.
A blend of tesamorelin and ipamorelin combining GHRH-receptor and ghrelin-receptor mechanisms.
Thymic peptide preparations studied for effects on T-cell differentiation and immune ageing.
A 28-amino-acid thymic peptide studied extensively as an immune modulator.
A long-acting GnRH agonist studied for receptor downregulation kinetics.
Save up to 25% on orders of 10+ boxes. Message us with the compounds and quantities you need and we will send a quote the same working day. See wholesale pricing →
This website sells laboratory research chemicals. Everything on it is intended for qualified researchers and is not for human or veterinary consumption.
We are sorry — you must be at least 21 years old to view this site. Please close this window.
By entering you confirm you are at least 21 years of age, that you will use all products for laboratory research purposes only, and that you accept our Terms of Sale, Privacy Policy and Research Disclaimer.
